Disclaimer: Kindly use this only for educational purposes. Doctor’s advice is mandatory before you take any medical decision. I’m using this to raise awareness about health insurance in the Indian market.

Disclaimer: Kindly use this only for educational purpose. Doctors advice is mandatory before you take any medical decision. I am using this to create health insurance awareness in India market.

Why I made diabetes calculator?

I have been providing financial advice to Indians and Non-Resident Indians (NRIs) through VenkatFin.com, and I have observed that individuals often rely on corporate group health and term insurance until they experience significant health issues. When you have a lifestyle disease like diabetes, BP, asthma, or cholesterol, that’s the right time to buy health or term insurance. Don’t search for it after you suffer a major health setback.

This is a small effort I am taking to create health insurance awareness in the Indian market.

How to find your HbA1C?

The best way to check HbA1C levels is to take a test in a nearby lab or clinic. The information provided below is only an estimate. Warning – Speak to a Doctor before you take any medical decision.

Message Venkat to get genuine term insurance, health insurance, and investment advice. *Paid consulting.

WhatsApp me: (91) 9384716268

Thank You,

Venkat

The post Diabetes Calculator appeared first on Healthcare CEO.

Ben Shahshahani, Ph.D., a technology executive with more than 20 years of experience in AI and machine learning, will serve as Vice President, Chief Artificial Intelligence Officer, starting Aug. 12, 2024. He will report to Chief Digital Officer Rohit Chandra, Ph.D.

In this newly created role, Dr. Shahshahani will work closely with other executives, clinical leaders and data scientists to drive Cleveland Clinic’s AI vision of transforming healthcare delivery.

Among his responsibilities, he will lead the development and execution of an enterprise AI strategy, focusing on opportunities where AI can help transform patient care, caregiver experience, and organizational efficiencies, while ensuring that the use of AI puts safety first, and adheres to industry regulations, ethical considerations, and data security best practices.

“Cleveland Clinic sees great promise for artificial intelligence in healthcare, as it has the ability to improve care for patients and streamline work for caregivers,” said Dr. Chandra. “However, we need to be thoughtful about how we implement it. Ben has a track record of effectively and strategically applying new technologies to create beneficial change for organizations. We are excited to bring his expertise to Cleveland Clinic.”

Dr. Shahshahani joins Cleveland Clinic from SiriusXM and Pandora, where he served as Sr. Vice President of Science, Machine Learning and Product Analytics since 2021. In that role, he led teams that delivered machine learning solutions to – and analytical insights about – SiriusXM’s products. Their accomplishments include the development of new deep learning and Generative AI techniques for spoken language processing and sequential modeling, and personalized content recommendations for users.

“I am looking forward to joining Cleveland Clinic and working collaboratively across teams to advance the understanding and use of artificial intelligence in healthcare in a way that benefits patients and caregivers,” said Dr. Shahshahani.

In previous leadership appointments, Dr. Shahshahani served at Verizon Media/Yahoo from 2014–2021 as Vice President of Advertising Science, Search & Ad Targeting Engineering, and later as Head of Yahoo Research. Before that, he led teams at Google focused on targeting and ad campaign optimization. His technology career also includes past roles at Nuance and IBM with expertise that spans research and engineering in machine learning and AI, in areas such as search, advertising, speech, natural language processing, and personalization.

Dr. Shahshahani earned his Ph.D. in Electrical Engineering from Purdue University in West Lafayette, Ind. He is credited with numerous patents, publications and speaking engagements related to speech and natural language processing, search, and online advertising.

Venkat

The post Cleveland Clinic Names First Chief AI Officer appeared first on Healthcare CEO.

Proteins are the workhorses of the cellular world, playing a critical role in virtually every biological process. From enzymes that power our metabolism to antibodies that fight off infection, proteins are the intricate machines that keep us alive. But what if we could design proteins with entirely new functions or optimize existing ones to be more efficient or effective? This is the ambitious goal of protein engineering, a field that has the potential to revolutionize everything from medicine and agriculture to materials science and biofuels.

One of the biggest challenges in protein engineering has been the complexity of the process. Proteins are complex three-dimensional structures, and even small changes in their amino acid sequence can have dramatic effects on their function. This has made it difficult to predict how changes in a protein’s sequence will affect its properties.

Cradle Bio, a young startup based in Cambridge, Massachusetts, is developing a new protein engineering platform that aims to make the process of designing and engineering proteins faster, easier, and more accessible. Cradle’s platform uses a combination of machine learning and computational modeling to predict the effects of mutations on protein structure and function. This allows scientists to rapidly design and test new protein variants without the need for time-consuming and expensive experimental methods.

One of the key advantages of Cradle’s platform is its ability to optimize multiple protein properties at the same time. Traditionally, protein engineering has focused on optimizing a single property, such as an enzyme’s activity or an antibody’s affinity for a target antigen. However, Cradle’s platform can be used to identify protein variants that are optimized for multiple properties simultaneously. This could be used to develop enzymes that are not only more active but also more stable or antibodies that are both highly specific and potent.

Cradle’s platform is already being used by a number of leading pharmaceutical and biotechnology companies. These companies are using Cradle to design new drugs, improve existing therapies, and develop novel biomaterials. For example, one company is using Cradle to design enzymes that can be used to break down pollutants in the environment. Another company is using Cradle to develop new antibodies for cancer immunotherapy.

The potential applications of Cradle’s technology are vast. By making protein engineering faster, easier, and more accessible, Cradle could help to accelerate the development of new drugs, diagnostics, and materials. Cradle’s technology could also lead to the development of entirely new products and applications that we can’t even imagine yet.

In addition to its technological innovation, Cradle Bio is also committed to making protein engineering more accessible to a wider range of scientists. The company offers a cloud-based platform that can be accessed by scientists from anywhere in the world. Cradle also offers a variety of educational resources, including workshops and tutorials, to help scientists learn how to use its platform.

Cradle Bio’s mission is to democratize protein engineering and make it a tool that can be used by scientists of all levels. By making protein engineering faster, easier, and more accessible, Cradle has the potential to revolutionize the field of biotechnology and usher in a new era of innovation.

Venkat

The post How Cradle Bio is Making Protein Design Accessible? appeared first on Healthcare CEO.

In a significant advancement in the fight against tuberculosis (TB), researchers at the Indian Institute of Science (IISc), in collaboration with the National Centre for Biological Sciences (NCBS) and the Institute for Stem Cell Biology and Regenerative Medicine (InStem), have identified a key mechanism that enables the tuberculosis bacterium to persist in human hosts for extended periods. This discovery, published in Science Advances, revolves around a single gene crucial for the production of iron-sulphur clusters in the Mycobacterium tuberculosis (Mtb) bacterium.

Tuberculosis, caused by Mtb, can reside in the human body for decades without manifesting any symptoms. The bacterium’s survival strategy involves hiding within oxygen-limited areas in the lungs, entering a dormant state where it neither divides nor engages in active metabolism. This state of dormancy allows Mtb to evade the immune system and the effects of TB drugs. As Mayashree Das, the first author and a Ph.D. student at the Department of Microbiology and Cell Biology (MCB) at IISc, explains, understanding this persistence is crucial for eradicating TB.

Amit Singh, an Associate Professor at MCB and the study’s corresponding author, led the team in cultivating Mtb under controlled conditions. They focused on the role of iron-sulphur clusters, essential for several proteins in Mtb, facilitating vital cellular reactions like respiration and carbon metabolism. These clusters, comprising iron and sulphur atoms in various configurations, are predominantly produced by the SUF operon in Mtb. However, another single gene, IscS, also contributes to their production, raising questions about its specific role.

Investigating this, the researchers created a mutant version of Mtb lacking the IscS gene. They discovered that under normal and low-oxygen conditions, the IscS gene is primarily responsible for producing iron-sulphur clusters. However, under oxidative stress, where the iron atoms in the clusters become oxidized, the SUF operon is activated to meet the increased demand for new clusters. This finding revealed the dual mechanism by which Mtb manages the production of these crucial clusters.

The study further explored how the absence of the IscS gene affects disease progression. In mice models infected with the mutant Mtb strain, the absence of IscS led to a severe form of the disease rather than the typical persistent, chronic TB infection. This was attributed to the unregulated activation of the SUF operon, resulting in hypervirulence. Remarkably, depleting both IscS and the SUF system significantly reduced Mtb persistence in mice, indicating the critical role of IscS in regulating the activation of the SUF operon and thus influencing TB persistence.

Additionally, the researchers observed that bacteria lacking the IscS gene were more susceptible to certain antibiotics. This insight opens new avenues for exploring combined therapeutic strategies using antibiotics and drugs targeting the IscS and SUF systems. Singh expresses optimism that a deeper understanding of these systems in Mtb could eventually lead to effective strategies for eradicating TB persistence.

REFERENCE:
Das M, Sreedharan S, Shee S, Nandy N, Banerjee U, Kohli S, Rajmani SR, Chandra N, Seshasayee ASN, Laxman S, and Amit Singh, Cysteine desulphurase (IscS)–mediated fine-tuning of bioenergetics and SUF expression prevents Mycobacterium tuberculosis hypervirulence, Science Advances (2023).

Press release from IISc

Venkat

Advertise

Paid Financial Consulting to choose right insurance and mutual fund

The post Breakthrough in TB Research: IISc Team Unveils Key Mechanism of Bacterial Persistence appeared first on Healthcare CEO.

What is radiomics? About Quibim’s purpose

1. QP-Prostate®: This AI solution integrates with PACS systems to revolutionize prostate MRI readings. It provides precise, quantitative information, automates tasks, and ensures PI-RADS compliance, aiding radiologists in making more informed, standardized decisions.
2. QP-Brain®: Designed for brain diagnosis, QP-Brain® brings an innovative approach to volumetrics and White Matter Hyperintensity (WMH) Analysis. It offers objective analysis, precise volume, and morphometry calculations for disease classification and progression.
3. Quibim Precision®: This software offers a comprehensive range of applications, from disease detection to tracking treatment efficacy. It integrates seamlessly into clinical routines, allowing for pre-reporting results through AI in radiology. Quibim Precision® provides unique analysis suites tailored to various body organ systems.

Quibim collaborates with top-tier biopharma companies and healthcare institutions to glean insights into cancer and other diseases. Their technology supports the development of prognostic or predictive models, bridging the gap between research and personalized care.

Advertise

The post Quibim’s Impact on Medical Diagnostics: What is radiomics? appeared first on Healthcare CEO.

Innovations in Personalized Medicine

Kemet Group’s approach to healthcare is innovative and patient-centric. They specialize in connecting individuals with pharmacies capable of creating customized medications. This includes unique dosages, formulations, and solutions for out-of-stock medications, exclusively serving residents of Alberta. Their pioneering work has not gone unnoticed, as they have garnered several prestigious awards, including the 2021 MIT Solve Global Challenges Award for Health Security & Pandemics, a second place in the 2022 Zeton/CSChE Plant Design Competition, and recognition from the University of Alberta’s Faculty of Pharmacy & Pharmaceutical Science.

KemNet’s Role in Drug Reformulation

KemNet, a key component of Kemet Group, specializes in supplying pharmacies with premium reformulations of popular drugs tailored for specific patient groups. These reformulated products address various health issues, such as erectile dysfunction, hair growth, pain management, weight loss, and women’s health. Notably, their erectile dysfunction medications are acclaimed for being up to eight times faster than traditional alternatives. This innovative approach is not only beneficial for patients but also advantageous for pharmacies, contributing to their financial growth.

Founder’s Vision and Expertise

The vision behind KemNet is driven by Morẹ́nikẹ́ Ọláòṣebìkan, a licensed clinical pharmacist and pharmacy proprietor. Her role as a Clinical Academic Colleague at the Faculty of Pharmacy & Pharmaceutical Sciences, University of Alberta, highlights her commitment to advancing the field of pharmacy through innovative practices. Her leadership has been instrumental in developing KemNet as a platform for pharmacies to access these specialized medications.

Business Model and Patient Empathy

KemNet operates with a unique business model, positioning itself as the “Amazon” for customized medications. This model emphasizes empathy in patient care, leading to the development of medications that are not only effective but also enjoyable to use, with reduced side effects. The company’s focus on empathetic design in medication formulation, derived from Ọláòṣebìkan’s experience as a multi-pharmacy owner, has proven to be a successful strategy for both patient care and business growth.

Summary

Kemet Group, through KemNet, exemplifies the potential of personalized medicine in improving patient care and pharmacy practices. Their innovative approach to drug reformulation and distribution, combined with a strong emphasis on patient empathy, positions them as a trailblazer in the healthcare industry. With their unique solutions and patient-centered approach, Kemet Group is set to continue making significant contributions to personalized healthcare and pharmacy services.

Advertise

The post How Kemet Group is Changing the Face of Personalized Medicine? appeared first on Healthcare CEO.